• Cancel
    Date：2026-01
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=921

    Recently, CAStar Foods, a leader in China’s biosynthetic human-derived bioactive protein industry, announced the closing of a Series A+ financing round worth several hundred million RMB. The company’s independently developed A60 bioactive peptide replicates rare core protein fragments found in breast milk, boasting immense potential in the fields of nutritional immunology and health. Proceeds from this financing round will be mainly allocated to advancing the industrialization of the company’s core functional protein/peptide products and their global market expansion. CEC Capital acted as the exclusive financial advisor to CAStar Foods for this transaction.

  • Cancel
    Date：2026-01
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=919

    Recently, MicroCyto announced the closing of a new round of equity financing worth nearly 300 million RMB. The investors include Beijing New Materials Industry Investment Fund, Beijing Medical and Health Industry Investment Fund, Zhongguancun Capital, and